Vesper Bio reports positive topline results for dementia candidate
November 7, 2025Research and Development Frontotemporal degeneration, Vesper Bio, clinical trials, dementia
Vesper Bio, a clinical-stage biotech developing novel oral therapies for neurodegenerative and neuropsychiatric disorders, has reported positive topline data from …
AAX Biotech and ToxoTech partner to develop next-gen biotherapeutics for neurological disorders
November 7, 2025Research and Development AAX Biotech, Biotherapeutics, ToxoTech, neurological disorders
AAX Biotech, a biotech company specialising in next-generation antibody therapeutics, has entered a strategic partnership with ToxoTech, a biopharma company …
Ardena appoints new Chief Quality Officer and Chief Information Officer
November 6, 2025Ardena, CDMO, CRO, Chief Information Officer, chief quality officer
Ardena, a specialist pharmaceutical contract development and manufacturing organisation (CDMO) and bioanalytical contract research organisation (CRO) focusing on precision medicines, …
Draig Therapeutics appoints Ivana Magovčević-Liebisch as President and CEO
November 5, 2025Draig Therapeutics, Neuropsychiatry, neuroscience
Draig Therapeutics, a Welsh clinical-stage company developing glutamate and GABA-based treatments for neuropsychiatry, has appointed Ivana Magovčević-Liebisch as President and …
Von Willebrand disease – increasing awareness and access to vital care
November 4, 2025Medical Communications, Research and Development European Medicines Association, Haematology, Takeda, Von Willebrand Disease, clinical trials, disease awareness
Pharmafile talks to Anthea Cherednichenko, Vice President Franchise Head Haematology and Transplant at Takeda about Von Willebrand disease, its causes …
Rethinking oncology trial endpoints with generalised pairwise comparisons
November 4, 2025Research and Development EMA, FDA, Oncology, One2Treat, clinical trials, generalised pairwise comparisons, net treatment benefit, oncology
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival (OS) and progression-free survival (PFS) …
VALANX Biotech appoints Klaus Orlinger as Chief Scientific Officer
November 4, 2025Antibody-Drug Conjugate, VALANX Biotech, drug development
VALANX Biotech, a company developing novel technology for site-specific protein conjugation in drug discovery, has appointed Klause Orlinger as Chief …
The Pharma Files: with Dr Ewen Cameron, Chief Executive of West Suffolk NHS Foundation Trust
November 3, 2025Medical Communications, Research and Development Corporate, NHS, The Pharma Files, healthcare professionals, patient care, patients
Pharmafile chats with Dr Ewen Cameron, Chief Executive of West Suffolk NHS Foundation Trust, about the best parts of his …
Five Facts about men’s mental health
October 31, 2025Medical Communications Five Facts, mental health, men’s mental health
1 While only 15.4% of men are diagnosed with a common mental health condition (CMHC’s) in the UK (compared to …
AAX Biotech and Daiichi Sankyo partner to evaluate antibody therapeutics
October 31, 2025AAX Biotech, Daiichi Sankyo, Opti-mAb, Seqitope
AAX Biotech, a Swedish biotechnology company specialising in next-generation antibody therapeutics, has launched a strategic partnership with Daiichi Sankyo, a …
Landmark Bio and Mass General Brigham partner to accelerate translational CGT therapies
October 30, 2025Research and Development Landmark Bio, Mass General Brigham, cell and gene therapies, partnership
Landmark Bio and Mass General Brigham in the US have entered a new strategic collaboration designed to accelerate the development …
Is this an Oppenheimer moment for the life sciences industry?
October 29, 2025Business Services, Market Access, Market Access Consultancy, Sales and Marketing NHS, Visions4Health
By Sabina Syed, Managing Director at Visions4Health In the history of science, few initiatives demonstrate the magnitude of coordinated effort …
Pharma&’s ovarian cancer therapy approved for use by NHS Scotland
October 29, 2025Pharma&, Rubraca, Scottish Medicines Consortium, nhs scotland, oncology, ovarian cancer
Pharma& has announced that its treatment for ovarian cancer, Rubraca (rucaparib), has been accepted by the Scottish Medicines Consortium (SMC) …
BioMedX launches R&D accelerator to advance women’s health
October 28, 2025Research and Development BioMedX, Gates Foundation, Women’s Health
BioMed X, an independent research institute with sites in Germany and the United States, has announced the launch of XFem …
Berlin Heals appoints Dr Eric Fain as new board member
October 28, 2025Berlin Heals, Cardiovascular Health, chronic heart failure, medtech
Berlin Heals, a clinical-stage medical device company focused on treating chronic heart failure, has appointed Dr Eric S Fain to …
Turning a 10-Year Vision into a 10-Year Plan
October 27, 2025Business Services, Market Access, Market Access Consultancy Corporate, Gateway to Local Adoption, NHS, Pharmacy, Population Health Management, Visions4Health, pharmacy
In the sixth of the Gateway to Local Adoption series, Visions4Health’s Head of Client Services, Jonny Savage, shares his views …
Sharp invests $100m in US and EU manufacturing and packaging facilities
October 27, 2025Manufacturing and Production EU, Sharp Services, US, manufacturing and packaging
Sharp Services, a pharmaceutical packaging and sterile manufacturing specialist, has announced investments totalling $100m across its US and European facility …
NNIT partners with global biopharma company for regulatory registration management
October 24, 2025Business Services IT, NNIT, digital solutions, regulatory
NNIT, a Danish provider of digital software and IT services, has entered a long-term strategic partnership with a global biopharmaceutical …
THX Pharma and Exeltis announce first milestone achieved for neurological disease treatment
October 23, 2025Research and Development Neurological Diseases, THX Pharma, Theranexus
THX Pharma (Theranexus), a pharma company focusing on developing treatments for rare neurological disease, and Exeltis, a pharma company within …
Excellence in Healthcare Partnerships (EHP) Awards Networking Event
October 23, 2025Medical Communications EHP Awards
From plan to partnership: navigating the enablers and challenges of collaborative working. How has the 10-year healthcare plan and Life …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
